Scholarlink

Background <p>For more than a decade after the ToGA trial, trastuzumab plus platinum-fluoropyrimidine chemotherapy remained the only established first-line HER2-targeted standard for unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma. The treatment landscape is now changing rapidly through pembrolizumab-based chemoimmunotherapy, zanidatamab-based therapy, and antibody-drug conjugate strategies.</p> Methods <p>This narrative review summarizes pivotal and emerging evidence for first-line HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma. PubMed/MEDLINE was searched through June 2026 using combinations of the terms HER2, gastric cancer, gastroesophageal junction, first-line treatment, trastuzumab, pembrolizumab, zanidatamab, tislelizumab, and trastuzumab deruxtecan. Priority was given to phase III trials, peer-reviewed reports, major conference updates, and guideline documents relevant to clinical practice.</p> Results <p>ToGA established trastuzumab plus chemotherapy as a first-line standard, but subsequent attempts to improve outcomes by adding or substituting HER2-directed agents, including lapatinib, high-dose trastuzumab, pertuzumab, and trastuzumab emtansine, did not displace trastuzumab-based therapy. KEYNOTE-811 demonstrated that pembrolizumab added to trastuzumab and chemotherapy improves response, progression-free survival, and overall survival, particularly in PD-L1-positive disease. The phase III HERIZON-GEA-01 trial has now shown that zanidatamab plus chemotherapy, with or without tislelizumab, improves progression-free survival compared with trastuzumab plus chemotherapy, and that zanidatamab plus tislelizumab and chemotherapy improves overall survival. Trastuzumab deruxtecan is also moving from later-line therapy into first-line development through platinum-free combinations with fluoropyrimidine and immune checkpoint blockade.</p> Conclusions <p>First-line treatment of HER2-positive advanced gastric cancer is entering a second transformation. The central clinical question is shifting from whether HER2 blockade should be combined with chemotherapy to which HER2-targeted platform should anchor first-line therapy, how immune checkpoint inhibition should be integrated, and how HER2 heterogeneity and biomarker evolution should guide treatment sequencing.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Redefining First-Line HER2-Positive Advanced Gastric Cancer: From Trastuzumab-Based Chemoimmunotherapy to Zanidatamab and Next-Generation HER2 Targeting

  • 期刊论文

  • 发表日期：

    2026年8月5日

查看全文
  • Tamotsu Sagawa,
  • Masahiro Hirakawa,
  • Hiroyuki Nagashima,
  • Koshi Fujikawa

摘要

Background

For more than a decade after the ToGA trial, trastuzumab plus platinum-fluoropyrimidine chemotherapy remained the only established first-line HER2-targeted standard for unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma. The treatment landscape is now changing rapidly through pembrolizumab-based chemoimmunotherapy, zanidatamab-based therapy, and antibody-drug conjugate strategies.

Methods

This narrative review summarizes pivotal and emerging evidence for first-line HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma. PubMed/MEDLINE was searched through June 2026 using combinations of the terms HER2, gastric cancer, gastroesophageal junction, first-line treatment, trastuzumab, pembrolizumab, zanidatamab, tislelizumab, and trastuzumab deruxtecan. Priority was given to phase III trials, peer-reviewed reports, major conference updates, and guideline documents relevant to clinical practice.

Results

ToGA established trastuzumab plus chemotherapy as a first-line standard, but subsequent attempts to improve outcomes by adding or substituting HER2-directed agents, including lapatinib, high-dose trastuzumab, pertuzumab, and trastuzumab emtansine, did not displace trastuzumab-based therapy. KEYNOTE-811 demonstrated that pembrolizumab added to trastuzumab and chemotherapy improves response, progression-free survival, and overall survival, particularly in PD-L1-positive disease. The phase III HERIZON-GEA-01 trial has now shown that zanidatamab plus chemotherapy, with or without tislelizumab, improves progression-free survival compared with trastuzumab plus chemotherapy, and that zanidatamab plus tislelizumab and chemotherapy improves overall survival. Trastuzumab deruxtecan is also moving from later-line therapy into first-line development through platinum-free combinations with fluoropyrimidine and immune checkpoint blockade.

Conclusions

First-line treatment of HER2-positive advanced gastric cancer is entering a second transformation. The central clinical question is shifting from whether HER2 blockade should be combined with chemotherapy to which HER2-targeted platform should anchor first-line therapy, how immune checkpoint inhibition should be integrated, and how HER2 heterogeneity and biomarker evolution should guide treatment sequencing.